

# Autologous Myoblast and Muscle Cell Injection

## Table of Content

Purpose  
Description & Definitions  
Criteria  
Coding  
Document History  
References  
Special Notes  
Keywords

Effective Date 8/2008  
Next Review Date 2/2024  
Coverage Policy Medical 262  
Version 5

**All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.\*.**

## Purpose:

This policy addresses the medical necessity of Autologous Myoblast and Muscle Cell Injection

## Description & Definitions:

Autologous Myoblast and Muscle Cell Injection is a procedure to biopsy a muscle and cultured before injecting into to another muscle to assist with regenerating damaged tissue.

## Criteria:

Autologous Myoblast and Muscle Cell Injection is considered **not medically necessary** for any indication.

## Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
53899	Unlisted procedure, urinary system.

## Document History:

### Revised Dates:

- 2020: January
- 2016: January
- 2015: March, August, September
- 2014: October
- 2013: January, March, April, May, July
- 2012: April, November
- 2010: March, April, August
- 2009: January, April

### Reviewed Dates:

- 2024: February
- 2023: February
- 2022: February
- 2021: February
- 2020: February
- 2018: November
- 2017: December
- 2014: April
- 2011: April
- 2010: July

### Effective Date:

- August 2008

## References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023, Sep 21). Retrieved Feb 13, 2024, from MCG: <https://careweb.careguidelines.com/ed27/index.html>

(2024). Retrieved Feb 13, 2024, from National Comprehensive Cancer Network: <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=muscle-derived%20cells>

(2024). Retrieved Feb 13, 2024, from Department of Medical Assistance Services - MES Public Portal: <https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=Cellular%20therapies&gsc.sort=>

(2024). Retrieved Feb 13, 2024, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=cell%20therapy&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance>

(2024). Retrieved Feb 13, 2024, from Hayes - a symplr company: <https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Autologous%2520cell%2520therapy%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%25>

(2024). Retrieved Feb 13, 2024, from Google - Specialty Guideline Search:  
[https://www.google.com/search?q=Professional+recommendations+for+Autologous+muscle-derived+cells&safe=strict&sca\\_esv=40ad471a4e6b196f&rlz=1C1GCEJ\\_enUS1093US1093&sxsrf=ACQVn09IM-MWpzn6k9SujGKxinKK9\\_fPw%3A1707848924728&ei=3LTLZfqBLKy5NoPz7CNwA4&ved=0ahUKE](https://www.google.com/search?q=Professional+recommendations+for+Autologous+muscle-derived+cells&safe=strict&sca_esv=40ad471a4e6b196f&rlz=1C1GCEJ_enUS1093US1093&sxsrf=ACQVn09IM-MWpzn6k9SujGKxinKK9_fPw%3A1707848924728&ei=3LTLZfqBLKy5NoPz7CNwA4&ved=0ahUKE)

Cellular & Gene Therapy Products. (2023, Mar 20). Retrieved Feb 13, 2024, from U.S. Food and Drug Administration: <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products>

NCD: Cellular Therapy (30.8). (N.D.). Retrieved Feb 13, 2024, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=6&ncdver=1&keyword=cell%20therapy&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=1>

Young, M., & Dijkstra, P. (2023, Jul 24). Biologic therapies for tendon and muscle injury. Retrieved Feb 13, 2024, from UpToDate: [https://www.uptodate.com/contents/biologic-therapies-for-tendon-and-muscle-injury?search=4.%09Autologous%20muscle-derived%20cells&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1#H1133988944](https://www.uptodate.com/contents/biologic-therapies-for-tendon-and-muscle-injury?search=4.%09Autologous%20muscle-derived%20cells&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1133988944)

### Special Notes: \*

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

### Keywords:

SHP Autologous Myoblast and Muscle Cell Injection, SHP Medical 262, incontinence, stress urinary incontinence, fecal incontinence, bowel incontinence, oral incontinence, autologous myoblast transplantation

